Related references
Note: Only part of the references are listed.Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study
C. Warren Olanow et al.
JOURNAL OF PARKINSONS DISEASE (2021)
Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease
Matthew Rosebraugh et al.
ANNALS OF NEUROLOGY (2021)
Epidemiology of skin event rates among users of pumps for the subcutaneous administration of drugs for chronic conditions
Susan S. Jick et al.
CURRENT MEDICAL RESEARCH AND OPINION (2021)
Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial
Regina Katzenschlager et al.
LANCET NEUROLOGY (2018)
Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features
K. Ray Chaudhuri et al.
MOVEMENT DISORDERS (2018)
Minimal Clinically Important Differences for the Experiences of Daily Living Parts of Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale
Krisztina Horvath et al.
MOVEMENT DISORDERS (2017)
Non-motor features of Parkinson disease
Anthony H. V. Schapira et al.
NATURE REVIEWS NEUROSCIENCE (2017)
Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa
Ahmed A. Othman et al.
JOURNAL OF PARKINSONS DISEASE (2017)
The impact of non-motor symptoms on the quality of life of Parkinson's disease patients: a longitudinal study
K. M. Prakash et al.
EUROPEAN JOURNAL OF NEUROLOGY (2016)
Effect of levodopa-carbidopa intestinal gel on dyskinesia in advanced Parkinson's disease patients
Angelo Antonini et al.
MOVEMENT DISORDERS (2016)
Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program
P. Odin et al.
PARKINSONISM & RELATED DISORDERS (2015)
Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: Final 12-Month, Open-Label Results
Hubert H. Fernandez et al.
MOVEMENT DISORDERS (2015)
Why do patients with Parkinson's disease fall? A cross-sectional analysis of possible causes of falls
Anette Schrag et al.
NPJ PARKINSONS DISEASE (2015)
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease
C. Warren Olanow et al.
MOVEMENT DISORDERS (2013)
Late-stage Parkinson disease
Miguel Coelho et al.
NATURE REVIEWS NEUROLOGY (2012)
On the nature of fear of falling in Parkinson's disease
S. Rahman et al.
BEHAVIOURAL NEUROLOGY (2011)
A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation
Angelo Antonini et al.
JOURNAL OF NEUROLOGY (2011)
Determination of Minimal Clinically Important Change in Early and Advanced Parkinson's Disease
Robert A. Hauser et al.
MOVEMENT DISORDERS (2011)
The scientific and clinical basis for the treatment of Parkinson disease (2009)
C. Warren Olanow et al.
NEUROLOGY (2009)
Parkinson's disease home diary: Further validation and implications for clinical trials
RA Hauser et al.
MOVEMENT DISORDERS (2004)
Health-related quality of Life and sleep disorders in Parkinson's disease
T Scaravilli et al.
NEUROLOGICAL SCIENCES (2003)
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
JE Ahlskog et al.
MOVEMENT DISORDERS (2001)
Hallucinations in Parkinson's disease -: Prevalence, phenomenology and risk factors
G Fénelon et al.
BRAIN (2000)
A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia
RA Hauser et al.
CLINICAL NEUROPHARMACOLOGY (2000)
Share Paper
